Home » Topics » BioWorld Science

BioWorld Science
RSS

Voronoi patents EGFR/JAK3 inhibitors

Oct. 4, 2019

Ethris and Munster University Hospital receive support for work in primary ciliary dyskinesia

Oct. 4, 2019

New arginase inhibitors identified at Merck & Co.

Oct. 4, 2019

Universita degli Studi di Siena discovers new antivirals

Oct. 4, 2019

Black Diamond Therapeutics describes preclinical activity of mutant EGFR/HER2 inhibitor BDTX-189

Oct. 4, 2019

Phase I safety and PK data presented for novel CXCR4 antagonist YF-H-2015005

Oct. 4, 2019

TERT gene fusions as novel biomarkers in metastatic Leydig cell tumors

Oct. 4, 2019

AL-008 potentiates the antitumor effector functions of macrophages and dendritic cells

Oct. 4, 2019

FDA approves Entresto for pediatric heart failure

Oct. 4, 2019

Allogene Therapeutics initiates phase I study of ALLO-715

Oct. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...